Advertisement
Advertisement
U.S. Markets open in 7 hrs 3 mins
Advertisement
Advertisement
Advertisement
Advertisement

TXMD Jan 2023 2.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.10000.0000 (0.00%)
As of 03:43PM EDT. Market open.
Advertisement
Full screen
Previous Close0.1000
Open0.1000
Bid0.0000
Ask0.2000
Strike2.50
Expire Date2023-01-20
Day's Range0.1000 - 0.2000
Contract RangeN/A
Volume25
Open Interest584
  • Business Wire

    TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

    BOCA RATON, Fla., September 12, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O’Dowd as the Company’s Chief Executive Officer.

  • Motley Fool

    TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript

    Good morning, everyone, and thank you for joining today to discuss our second quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing its second quarter 2022 financial results. The press release and accompanying presentation are available on the company's website TherapeuticsMD in the investors and media section.

  • Zacks

    TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

    TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement